// Auto-generated - do not edit
export const substanceName = "Bromazepam";
export const sources = [{"id":"drugbank","fileName":"DRUGBANK - Bromazepam.md","displayName":"DrugBank","size":18522},{"id":"erowid","fileName":"EROWID - Bromazepam.md","displayName":"Erowid","size":3411},{"id":"protestkit","fileName":"PROTESTKIT - Bromazepam.json","displayName":"Protest Kit","size":3788},{"id":"psychonautwiki","fileName":"PSYCHONAUTWIKI - Bromazepam.md","displayName":"PsychonautWiki","size":18189},{"id":"tripsit-factsheets","fileName":"TRIPSIT_FACTSHEETS - Bromazepam.md","displayName":"TripSit Factsheets","size":488},{"id":"wikipedia","fileName":"WIKIPEDIA - Bromazepam.md","displayName":"Wikipedia","size":11466}];
export const contents: Record<string, string> = {
  "drugbank": `# Bromazepam
*Source: https://go.drugbank.com/drugs/DB01558*

## Overview

### Description

This compound belongs to the class of organic compounds known as 1,4-benzodiazepines. These are organic compounds containing a benzene ring fused to a 1,4-azepine.

### Background

One of the benzodiazepines that is used in the treatment of anxiety disorders. It is a Schedule IV drug in the U.S. and Canada and under the Convention on Psychotropic Substances. It is a intermediate-acting benzodiazepine.

### Indication

For the short-term treatment of insomnia, short-term treatment of anxiety or panic attacks, if a benzodiazepine is required, and the alleviation of the symptoms of alcohol- and opiate-withdrawal.

### Pharmacodynamics

Bromazepam is a lipophilic, long-acting benzodiazepine and with sedative, hypnotic, anxiolytic and skeletal muscle relaxant properties. It does not possess any antidepressant qualities. Bromazepam, like other benzodiazepines, presents a risk of abuse, misuse, and dependence. According to many psychiatric experts, Bromazepam has a greater abuse potential than other benzodiazepines because of fast resorption and rapid onset of action.

### Mechanism of Action

GABA(A) Receptor
Positive allosteric modulator
GABA(A) Receptor Benzodiazepine Binding Site
Ligand

### Absorption

Bioavailability is 84% following oral administration. The time to peak plasma level is 1 - 4 hours. Bromazepam is generally well absorbed after oral administration.

### Metabolism

Hepatically, via oxidative pathways (via an enzyme belonging to the Cytochrome P450 family of enzymes). One of the main metabolites is 3-hydroxybromazepam. It is pharmacologically active and the half life is similar to that of the parent compound.

### Half-life

10-20 hours

### Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

1,2-Benzodiazepine
The risk or severity of CNS depression can be increased when Bromazepam is combined with 1,2-Benzodiazepine.
Abacavir
Abacavir may decrease the excretion rate of Bromazepam which could result in a higher serum level.
Abametapir
The serum concentration of Bromazepam can be increased when it is combined with Abametapir.
Abatacept
The metabolism of Bromazepam can be increased when combined with Abatacept.
Abiraterone
The serum concentration of Bromazepam can be increased when it is combined with Abiraterone.

### Food Interactions

Avoid alcohol. Ingesting alcohol may increase the sedative and CNS depressant effects of bromazepam.
Take with or without food. Taking bromazepam with food may reduce its Cmax and AUC.

## Chemical Information

**DrugBank ID:** DB01558

**Synonyms:** Bromacepam
Bromazepam
Bromazepamum

**Chemical Formula:** C
14
H
10
BrN
3
O

**SMILES:** BrC1=CC2=C(NC(=O)CN=C2C2=CC=CC=N2)C=C1

**Weight:** Average: 316.153
Monoisotopic: 315.000724604

**IUPAC Name:** 7-bromo-5-(pyridin-2-yl)-2,3-dihydro-1H-1,4-benzodiazepin-2-one

## Additional Information

### Modality

Small Molecule

### Patents

0

### Indicated Conditions

2

### Phase 0

0

### Phase 1

0

### Phase 2

0

### Phase 3

2

### Phase 4

0

### Therapeutic Categories

Benzodiazepines and benzodiazepine
derivatives

### Summary

Bromazepam
is a short-acting benzodiazepine with intermediate onset commonly used to treat panic disorders and severe anxiety.

### Generic Name

Bromazepam

### DrugBank Accession Number

DB01558

### Groups

Approved, Illicit

### Structure

3D
Download
MOL
SDF
3D-SDF
PDB
SMILES
InChI
Similar Structures
Structure for Bromazepam (DB01558)
×
Close

### External IDs

RO 5-3350
RO-5-3350

### Associated Conditions

Indication Type
Indication
Combined Product Details
Approval Level
Age Group
Patient Characteristics
Dose Form
Symptomatic treatment of
Acute anxiety
••••••••••••
Create Account
Symptomatic treatment of
Severe anxiety
••••••••••••
Create Account
Create Account

### Mechanism of action

Bromazepam binds to the GABA-A receptor producing a conformational change and potentiating its inhibitory effects. Other neurotransmitters are not influenced.
Target
Actions
Organism
A
GABA(A) Receptor
positive allosteric modulator
Humans
A
GABA(A) Receptor Benzodiazepine Binding Site
ligand
Humans

### Volume of distribution

1.56 L/kg

### Protein binding

70%

### Route of elimination

Urine (69%), as metabolites

### Clearance

0.82 mL/min/kg.

### International/Other Brands

Calmepam
/
Creosedin
/
Durazanil
/
Lectopam
/
Lekotam
/
Lexaurin
/
Lexilium
/
Lexomil
/
Lexotan
/
Normoc
/
Ultramidol

### Brand Name Prescription Products

Name
Dosage
Strength
Route
Labeller
Marketing Start
Marketing End
Region
Image
Bromazepam
Tablet
3 mg
Oral
Apotex Corporation
1995-12-31
Not applicable
Canada
Bromazepam
Tablet
1.5 mg
Oral
Apotex Corporation
1995-12-31
Not applicable
Canada
Bromazepam
Tablet
6 mg
Oral
Apotex Corporation
1995-12-31
Not applicable
Canada
Bromazepam-1.5 - Tab 1.5mg
Tablet
1.5 mg
Oral
Pro Doc Limitee
1997-05-20
2010-07-13
Canada
Bromazepam-3 - Tab 3mg
Tablet
3 mg
Oral
Pro Doc Limitee
1996-12-04
2019-04-10
Canada

### Generic Prescription Products

Name
Dosage
Strength
Route
Labeller
Marketing Start
Marketing End
Region
Image
Alti-bromazepam 1.5mg Tablets
Tablet
1.5 mg
Oral
Altimed Pharma Inc.
1996-12-31
2005-05-27
Canada
Alti-bromazepam 3mg Tablets
Tablet
3 mg
Oral
Altimed Pharma Inc.
1995-12-31
2005-05-27
Canada
Alti-bromazepam 6mg Tablets
Tablet
6 mg
Oral
Altimed Pharma Inc.
1996-12-31
2005-05-27
Canada
Apo-bromazepam
Tablet
6 mg
Oral
Apotex Corporation
1995-12-31
Not applicable
Canada
Apo-bromazepam
Tablet
1.5 mg
Oral
Apotex Corporation
1995-12-31
Not applicable
Canada

### ATC Codes

N05BA08 — Bromazepam
N05BA — Benzodiazepine derivatives
N05B — ANXIOLYTICS
N05 — PSYCHOLEPTICS
N — NERVOUS SYSTEM

### Drug Categories

Anti-Anxiety Agents
Benzazepines
Benzodiazepine hypnotics and sedatives
Benzodiazepines and benzodiazepine derivatives
Benzodiazepinones
Central Nervous System Agents
Central Nervous System Depressants
Cytochrome P-450 CYP1A2 Substrates
Cytochrome P-450 CYP2C19 Substrates
Cytochrome P-450 CYP2E1 Inhibitors
Cytochrome P-450 CYP2E1 Inhibitors (strength unknown)
Cytochrome P-450 Enzyme Inhibitors
Cytochrome P-450 Substrates
Drugs that are Mainly Renally Excreted
GABA Agents
GABA Modulators
Heterocyclic Compounds, Fused-Ring
Hypnotics and Sedatives
Muscle Relaxants
Muscle Relaxants, Centrally Acting Agents
Nervous System
Neurotransmitter Agents
Psycholeptics
Psychotropic Drugs
Tranquilizing Agents

### Chemical TaxonomyProvided byClassyfire

Description
This compound belongs to the class of organic compounds known as 1,4-benzodiazepines. These are organic compounds containing a benzene ring fused to a 1,4-azepine.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzodiazepines
Sub Class
1,4-benzodiazepines
Direct Parent
1,4-benzodiazepines
Alternative Parents
Alpha amino acids and derivatives
/
Pyridines and derivatives
/
Benzenoids
/
Aryl bromides
/
Heteroaromatic compounds
/
Secondary carboxylic acid amides
/
Lactams
/
Ketimines
/
Propargyl-type 1,3-dipolar organic compounds
/
Azacyclic compounds
/
Organopnictogen compounds
/
Organobromides
/
Organic oxides
/
Hydrocarbon derivatives
/
Carbonyl compounds
show 5 more
Substituents
1,4-benzodiazepine
/
Alpha-amino acid or derivatives
/
Aromatic heteropolycyclic compound
/
Aryl bromide
/
Aryl halide
/
Azacycle
/
Benzenoid
/
Carbonyl group
/
Carboxamide group
/
Carboxylic acid derivative
/
Heteroaromatic compound
/
Hydrocarbon derivative
/
Imine
/
Ketimine
/
Lactam
/
Organic 1,3-dipolar compound
/
Organic nitrogen compound
/
Organic oxide
/
Organic oxygen compound
/
Organobromide
/
Organohalogen compound
/
Organonitrogen compound
/
Organooxygen compound
/
Organopnictogen compound
/
Propargyl-type 1,3-dipolar organic compound
/
Pyridine
/
Secondary carboxylic acid amide
show 17 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

### Kingdom

Organic compounds

### Super Class

Organoheterocyclic compounds

### Class

Benzodiazepines

### Sub Class

1,4-benzodiazepines

### Direct Parent

1,4-benzodiazepines

### Alternative Parents

Alpha amino acids and derivatives
/
Pyridines and derivatives
/
Benzenoids
/
Aryl bromides
/
Heteroaromatic compounds
/
Secondary carboxylic acid amides
/
Lactams
/
Ketimines
/
Propargyl-type 1,3-dipolar organic compounds
/
Azacyclic compounds
/
Organopnictogen compounds
/
Organobromides
/
Organic oxides
/
Hydrocarbon derivatives
/
Carbonyl compounds
show 5 more

### Substituents

1,4-benzodiazepine
/
Alpha-amino acid or derivatives
/
Aromatic heteropolycyclic compound
/
Aryl bromide
/
Aryl halide
/
Azacycle
/
Benzenoid
/
Carbonyl group
/
Carboxamide group
/
Carboxylic acid derivative
/
Heteroaromatic compound
/
Hydrocarbon derivative
/
Imine
/
Ketimine
/
Lactam
/
Organic 1,3-dipolar compound
/
Organic nitrogen compound
/
Organic oxide
/
Organic oxygen compound
/
Organobromide
/
Organohalogen compound
/
Organonitrogen compound
/
Organooxygen compound
/
Organopnictogen compound
/
Propargyl-type 1,3-dipolar organic compound
/
Pyridine
/
Secondary carboxylic acid amide
show 17 more

### Molecular Framework

Aromatic heteropolycyclic compounds

### Affected organisms

Humans and other mammals

### UNII

X015L14V0O

### CAS number

1812-30-2

### InChI Key

VMIYHDSEFNYJSL-UHFFFAOYSA-N

### InChI

InChI=1S/C14H10BrN3O/c15-9-4-5-11-10(7-9)14(17-8-13(19)18-11)12-3-1-2-6-16-12/h1-7H,8H2,(H,18,19)

### General References

Oelschlager H: [Chemical and pharmacologic aspects of benzodiazepines]. Schweiz Rundsch Med Prax. 1989 Jul 4;78(27-28):766-72. [
Article
]
Oda M, Kotegawa T, Tsutsumi K, Ohtani Y, Kuwatani K, Nakano S: The effect of itraconazole on the pharmacokinetics and pharmacodynamics of bromazepam in healthy volunteers. Eur J Clin Pharmacol. 2003 Nov;59(8-9):615-9. Epub 2003 Sep 27. [
Article
]
van Harten J: Overview of the pharmacokinetics of fluvoxamine. Clin Pharmacokinet. 1995;29 Suppl 1:1-9. doi: 10.2165/00003088-199500291-00003. [
Article
]
Ochs HR, Greenblatt DJ, Friedman H, Burstein ES, Locniskar A, Harmatz JS, Shader RI: Bromazepam pharmacokinetics: influence of age, gender, oral contraceptives, cimetidine, and propranolol. Clin Pharmacol Ther. 1987 May;41(5):562-70. [
Article
]
Lacy CF, Armstrong LL, Goldman MP, Lance LL eds (2007). Lexicomp drug information handbook (15th ed.). Lexicomp.

### External Links

Human Metabolome Database
HMDB0015511
KEGG Drug
D01245
PubChem Compound
2441
PubChem Substance
46505694
ChemSpider
2347
RxNav
1749
ChEBI
31302
ChEMBL
CHEMBL277062
ZINC
ZINC000000001051
Therapeutic Targets Database
DAP001035
PharmGKB
PA10035
Drugs.com
Drugs.com Drug Page
Wikipedia
Bromazepam

### Human Metabolome Database

HMDB0015511

### KEGG Drug

D01245

### PubChem Compound

2441

### PubChem Substance

46505694

### ChemSpider

2347

### RxNav

1749

### ChEBI

31302

### ChEMBL

CHEMBL277062

### ZINC

ZINC000000001051

### Therapeutic Targets Database

DAP001035

### PharmGKB

PA10035

### Drugs.com

Drugs.com Drug Page

### Wikipedia

Bromazepam

### Packagers

United States Pharmacopeial Convention Inc.

### Dosage Forms

Form
Route
Strength
Tablet
Oral
3.000 mg
Tablet
Oral
3 mg/1
Tablet
Oral
6 mg/1
Tablet
Oral
6 mg
Suspension
Oral
6 mg
Solution / drops
Oral
2.5 MG/ML
Tablet
Oral
1.5 MG
Tablet
Oral
3 MG
Tablet, film coated
Oral
Capsule
Oral
Solution / drops
Oral
Capsule
Oral
Capsule
Oral
1.5 MG
Capsule
Oral
12 MG
Capsule
Oral
3 MG
Capsule
Oral
6 MG
Tablet
Oral
300000 mg
Tablet
Oral
Tablet
Oral
3 mg / tab
Tablet
Oral
6.000 mg
Tablet
Oral
6 mg / tab

### Prices

Unit description
Cost
Unit
Lectopam 6 mg Tablet
0.25USD
tablet
Lectopam 3 mg Tablet
0.17USD
tablet
Apo-Bromazepam 6 mg Tablet
0.13USD
tablet
Gen-Bromazepam 6 mg Tablet
0.13USD
tablet
Novo-Bromazepam 6 mg Tablet
0.13USD
tablet
Apo-Bromazepam 3 mg Tablet
0.09USD
tablet
Gen-Bromazepam 3 mg Tablet
0.09USD
tablet
Novo-Bromazepam 3 mg Tablet
0.09USD
tablet
Apo-Bromazepam 1.5 mg Tablet
0.07USD
tablet
Gen-Bromazepam 1.5 mg Tablet
0.07USD
tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

### State

Solid

### Experimental Properties

Property
Value
Source
logP
2.05
SANGSTER (1994)

### Predicted Properties

Property
Value
Source
Water Solubility
0.0399 mg/mL
ALOGPS
logP
2.09
ALOGPS
logP
2.54
Chemaxon
logS
-3.9
ALOGPS
pKa (Strongest Acidic)
12.24
Chemaxon
pKa (Strongest Basic)
2.65
Chemaxon
Physiological Charge
0
Chemaxon
Hydrogen Acceptor Count
3
Chemaxon
Hydrogen Donor Count
1
Chemaxon
Polar Surface Area
54.35 Å
2
Chemaxon
Rotatable Bond Count
1
Chemaxon
Refractivity
76.99 m
3
·mol
-1
Chemaxon
Polarizability
28.11 Å
3
Chemaxon
Number of Rings
3
Chemaxon
Bioavailability
1
Chemaxon
Rule of Five
Yes
Chemaxon
Ghose Filter
Yes
Chemaxon
Veber's Rule
No
Chemaxon
MDDR-like Rule
No
Chemaxon

### Predicted ADMET Features

Property
Value
Probability
Human Intestinal Absorption
+
0.9937
Blood Brain Barrier
+
0.9848
Caco-2 permeable
+
0.7571
P-glycoprotein substrate
Substrate
0.5741
P-glycoprotein inhibitor I
Non-inhibitor
0.7251
P-glycoprotein inhibitor II
Non-inhibitor
0.924
Renal organic cation transporter
Non-inhibitor
0.558
CYP450 2C9 substrate
Non-substrate
0.8385
CYP450 2D6 substrate
Non-substrate
0.9117
CYP450 3A4 substrate
Substrate
0.7117
CYP450 1A2 substrate
Inhibitor
0.9381
CYP450 2C9 inhibitor
Non-inhibitor
0.6329
CYP450 2D6 inhibitor
Non-inhibitor
0.8511
CYP450 2C19 inhibitor
Non-inhibitor
0.5719
CYP450 3A4 inhibitor
Non-inhibitor
0.7405
CYP450 inhibitory promiscuity
High CYP Inhibitory Promiscuity
0.6441
Ames test
Non AMES toxic
0.8607
Carcinogenicity
Non-carcinogens
0.8704
Biodegradation
Not ready biodegradable
1.0
Rat acute toxicity
2.2416 LD50, mol/kg
Not applicable
hERG inhibition (predictor I)
Weak inhibitor
0.9974
hERG inhibition (predictor II)
Non-inhibitor
0.7977
ADMET data is predicted using
admetSAR
, a free tool for evaluating chemical ADMET properties. (
23092397
)

### Spectra

Spectrum
Spectrum Type
Splash Key
Predicted GC-MS Spectrum - GC-MS
Predicted GC-MS
splash10-000i-0091000000-cf3c3fba2d2e801551b1
Mass Spectrum (Electron Ionization)
MS
splash10-00n0-9463000000-abe7fdab778f08fe18c4
LC-MS/MS Spectrum - LC-ESI-QFT , negative
LC-MS/MS
splash10-03di-0049000000-67c4bd48b889caf68ca3
LC-MS/MS Spectrum - LC-ESI-QFT , negative
LC-MS/MS
splash10-000i-0090000000-8d6819f4db99e73f4dbe
LC-MS/MS Spectrum - LC-ESI-QFT , negative
LC-MS/MS
splash10-002r-6090000000-f5e0ef1096bea72d5c89
LC-MS/MS Spectrum - LC-ESI-QFT , negative
LC-MS/MS
splash10-004i-9010000000-19864d6c0a50c513bb18
LC-MS/MS Spectrum - LC-ESI-QFT , negative
LC-MS/MS
splash10-004i-9000000000-59557fda51a0ea2c63d7
LC-MS/MS Spectrum - LC-ESI-QFT , negative
LC-MS/MS
splash10-004i-9000000000-6b0acd4d149e1fb20f9a
LC-MS/MS Spectrum - LC-ESI-QFT , negative
LC-MS/MS
splash10-004i-9000000000-6b0acd4d149e1fb20f9a
LC-MS/MS Spectrum - LC-ESI-QFT , negative
LC-MS/MS
splash10-004i-9000000000-6b0acd4d149e1fb20f9a
LC-MS/MS Spectrum - LC-ESI-QFT , negative
LC-MS/MS
splash10-004i-9000000000-6b0acd4d149e1fb20f9a
LC-MS/MS Spectrum - LC-ESI-QTOF , positive
LC-MS/MS
splash10-014i-0379000000-14ceeb34a706f6a12f41
LC-MS/MS Spectrum - LC-ESI-QFT , positive
LC-MS/MS
splash10-014i-0009000000-09662342e908d558048e
LC-MS/MS Spectrum - LC-ESI-QFT , positive
LC-MS/MS
splash10-014i-0029000000-4b93291583996cb3cbda
LC-MS/MS Spectrum - LC-ESI-QFT , positive
LC-MS/MS
splash10-05o0-0492000000-035f589c482b481c5152
LC-MS/MS Spectrum - LC-ESI-QFT , positive
LC-MS/MS
splash10-053r-1890000000-1997ad0374625359f483
LC-MS/MS Spectrum - LC-ESI-QFT , positive
LC-MS/MS
splash10-053r-1960000000-4f105348e7e7804313ce
LC-MS/MS Spectrum - LC-ESI-QFT , positive
LC-MS/MS
splash10-053r-1930000000-b0f688a41f88a133b74b
LC-MS/MS Spectrum - LC-ESI-QFT , positive
LC-MS/MS
splash10-0f89-1910000000-c0dd1d47a44a292c87b6
LC-MS/MS Spectrum - LC-ESI-QFT , positive
LC-MS/MS
splash10-0fb9-2900000000-706d4c35cde468a8387d
LC-MS/MS Spectrum - LC-ESI-QFT , positive
LC-MS/MS
splash10-004i-6900000000-85795e315602b7e61a6b
Predicted MS/MS Spectrum - 10V, Positive (Annotated)
Predicted LC-MS/MS
splash10-014i-0009000000-99f4dfe5439d3dd8c80f
Predicted MS/MS Spectrum - 10V, Negative (Annotated)
Predicted LC-MS/MS
splash10-03di-0009000000-b2c47603b92e2e6a3ba0
Predicted MS/MS Spectrum - 20V, Negative (Annotated)
Predicted LC-MS/MS
splash10-03di-4009000000-5a053eaa9e6f8096bc0c
Predicted MS/MS Spectrum - 20V, Positive (Annotated)
Predicted LC-MS/MS
splash10-014i-0009000000-145bc9aa0c21e6a0e341
Predicted MS/MS Spectrum - 40V, Negative (Annotated)
Predicted LC-MS/MS
splash10-004i-9020000000-448369b122422b784871
Predicted MS/MS Spectrum - 40V, Positive (Annotated)
Predicted LC-MS/MS
splash10-052p-0490000000-ed76996c5885f708c7e0
Predicted 1H NMR Spectrum
1D NMR
Not Applicable
Predicted 13C NMR Spectrum
1D NMR
Not Applicable

### Chromatographic Properties

Collision Cross Sections (CCS)
Adduct
CCS Value (Å
2
)
Source type
Source
[M-H]-
163.6724324
predicted
DarkChem Lite v0.1.0
[M-H]-
157.40865
predicted
DeepCCS 1.0 (2019)
[M+H]+
164.2958324
predicted
DarkChem Lite v0.1.0
[M+H]+
159.80421
predicted
DeepCCS 1.0 (2019)
[M+Na]+
163.8897324
predicted
DarkChem Lite v0.1.0
[M+Na]+
165.81105
predicted
DeepCCS 1.0 (2019)

### Kind

Protein

### Organism

Humans

### Pharmacological action

Unknown

### Actions

Inhibitor

### Curator comments

Information regarding this enzyme action is limited in the literature at this time.

### General Function

A cytochrome P450 monooxygenase involved in the metabolism of fatty acids (PubMed:10553002, PubMed:18577768). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase) (PubMed:10553002, PubMed:18577768). Catalyzes the hydroxylation of carbon-hydrogen bonds. Hydroxylates fatty acids specifically at the omega-1 position displaying the highest catalytic activity for saturated fatty acids (PubMed:10553002, PubMed:18577768). May be involved in the oxidative metabolism of xenobiotics (Probable)

### Specific Function

4-nitrophenol 2-monooxygenase activity

### Gene Name

CYP2E1

### Uniprot ID

P05181

### Uniprot Name

Cytochrome P450 2E1

### Molecular Weight

56848.42 Da

`,
  "erowid": `# Bromazepam
*Source: https://www.erowid.org/pharms/bromazepam/bromazepam.shtml*

## Law
[PHARMS](https://erowid.org/pharms/)
 
[bromazepam](https://erowid.org/pharms/bromazepam/)
 
[Stunning Huichol Yarn Art Donate \$250 and get a beautiful Huichol yarn painting, hand made by Huichol artists in Mexico. A fabulous gift! (8, 12 & 24 inch pieces available.)](https://erowid.org/donations/gifts_yarn_art.php?src=ms349)
 
Bromazepam
 
Legal Status
 
by Erowid
 
U.S. FEDERAL LAW #
 
Caution : All legal information should be verified through other sources. [ see below ]
 
**U.S. FEDERAL LEGAL SUMMARY**
**Bromazepam**
- REGULATED: Yes
- STATUS: Scheduled
- SCHEDULE: Schedule IV
- CLASSIFICATION: Depressant
 
Bromazepam is Schedule IV in the U.S. This means it is illegal to sell without a license and illegal to possess without a valid license or prescription.
 
INTERNATIONAL LAW #
 
Canada #
 
Benzodiazepines (including bromazepam) are Schedule IV under Canadian law. See [http://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-26.html#h-29](http://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-26.html#h-29) . (thanks e) (last updated Jul 30 2012)
 
Czech Republic #
 
Bromazepam is available by prescription only in the Czech Republic.
 
Germany (Deutschland) #
 
Bromazepam is available by prescription only in Germany. Brand name "Bromazanil, produced by Hexal, available in packages of 20 tablets at 6 mg bromazepam each. (thanks P)
 
The Netherlands #
 
Most benzodiazepeines are available with a prescription in the Netherlands. Preparation, possession, adaption, delivery, providing and transport, of benzodiazepines are prohibited, because they are scheduled on "List II" of the "Opium Law". Possession of small quantities (for personal use) of prohibited substances is typically not prosecuted. Recreational use of benzodiazepines, is, as with any other substance, not prohibited in the Netherlands. Benzodiazepines approved for medical use in the Netherlands: Alprazolam, Bromazepam, Brotizolam, Chloordiazepoxide (in english chlordiazepoxide), Clobazam, Clonazepam, Clorazepinezuur (in english clorazepate), Diazepam, Flunitrazepam, Flurazepam, Loprazolam, Lorazepam, Lormetazepam, Midazolam, Nitrazepam, Oxazepam, Prazepam, Temazepam, as well as Zolpidem and Zopiclone. (thanks K) (last updated Oct 11, 2012)
 If you have information about the legal status of this substance in any other country, please [let us know.](mailto:submissions%40erowid.org?subject=legal status of . . .&body=Legal Info For: [enter substance name here])
 
CAUTION & DISCLAIMER #
 
Erowid legal information is a summary of data gathered from site visitors, government documents, websites, and other resources. We are not lawyers and can not guarantee the accuracy of the information provided here. We do our best to keep this information correct and up-to-date, but laws are complex and constantly changing. Laws may also vary from one jurisdiction to another (county, state, country, etc)...this list is not comprehensive.
 
RELATED RESOURCES #
 
RELATED LINKS #
 None
 
[ [back to pharms](https://erowid.org/pharms/) ] [ [back to bromazepam](https://erowid.org/pharms/bromazepam/) ]
 
- Created by Erowid - Jun 21, 2004 | Created by Erowid - Jun 21, 2004 | Modified - Feb 10, 2015
**Created by Erowid - Jun 21, 2004**
 
Content & design © 1995-2025 Erowid.org. Permission required before publicly reproducing Erowid info.`,
  "protestkit": `{
  "url": "https://drugs.tripsit.me/bromazepam",
  "experiencesUrl": "https://www.reddit.com/search/?q=Bromazepam",
  "name": "Bromazepam",
  "aliases": [
    "brazepam",
    "lectopam",
    "lexilium",
    "lexotan",
    "lexotanil"
  ],
  "aliasesStr": "brazepam,lectopam,lexilium,lexotan,lexotanil",
  "summary": "A benzodiazepine drug with a medium-long duration, developed by Roche in the 1960s. Has primarily anxiolytic properties. May cause lowered inhibitions and amnesia in high doses.",
  "reagents": null,
  "classes": {
    "chemical": [
      "Benzodiazepines"
    ],
    "psychoactive": [
      "Depressant"
    ]
  },
  "toxicity": null,
  "addictionPotential": null,
  "tolerance": null,
  "crossTolerances": null,
  "roas": [
    {
      "name": "Oral",
      "dosage": [
        {
          "name": "Light",
          "value": "2.5-5mg"
        },
        {
          "name": "Common",
          "value": "5-10mg"
        },
        {
          "name": "Heavy",
          "value": "10-15mg+"
        }
      ],
      "duration": [
        {
          "name": "Onset",
          "value": "0.17 - 0.33 hours"
        },
        {
          "name": "Duration",
          "value": "4.0 - 8.0 hours"
        },
        {
          "name": "After effects",
          "value": "1.0 - 16.0 hours"
        }
      ],
      "bioavailability": "84%"
    }
  ],
  "interactions": [
    {
      "name": "2C-T-x",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "2C-x",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "5-MeO-xxT",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "Alcohol",
      "status": "Dangerous"
    },
    {
      "name": "Amphetamines",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "Caffeine",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "Cannabis",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "Cocaine",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "DMT",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "DOx",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "DXM",
      "status": "Caution"
    },
    {
      "name": "GHB/GBL",
      "status": "Dangerous"
    },
    {
      "name": "Gabapentinoids",
      "status": "Unsafe"
    },
    {
      "name": "Ketamine",
      "status": "Caution"
    },
    {
      "name": "LSD",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "MAOIs",
      "status": "Low Risk & Synergy"
    },
    {
      "name": "MDMA",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "MMC class",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "MXE",
      "status": "Caution"
    },
    {
      "name": "Mescaline",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "Mushrooms",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "NBOMes",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "Nitrous",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "Opioids",
      "status": "Dangerous"
    },
    {
      "name": "PDA5",
      "status": "Caution"
    },
    {
      "name": "PVP class",
      "status": "Unsafe"
    },
    {
      "name": "Poppers",
      "status": "Unsafe"
    },
    {
      "name": "SSRIs",
      "status": "Low Risk & No Synergy"
    },
    {
      "name": "Tramadol",
      "status": "Dangerous"
    }
  ],
  "effects": "Anxiolytic, Sedative, Muscle Relaxant, Amnesia, Dystaxia.",
  "categorized_effects": {
    "Physical effects": [
      "Sedative",
      "Muscle Relaxant",
      "Dystaxia."
    ],
    "Mental effects": [
      "Anxiolytic",
      "Amnesia"
    ],
    "Sensory effects": [],
    "Uncategorized effects": []
  }
}`,
  "psychonautwiki": `# Bromazepam
*Source: https://psychonautwiki.org/wiki/Bromazepam*

## Dosage & Duration

### Oral

**Dosage:**
- Bioavailability: 84%[2]
- Threshold: < 1.5 mg
- Light: 1.5 - 3 mg
- Common: 3 - 6 mg
- Strong: 6 - 12 mg
- Heavy: 12 mg +

**Duration:**
- Total: 6 - 15 hours
- Onset: 14 - 15 minutes
- Come up: 15 - 120 minutes
- Peak: 2 - 12 hours
- Offset: 30 - 60 minutes
- After effects: 12 - 22 hours
**Fatal [overdose](https://psychonautwiki.org/wiki/Overdose) may occur when [benzodiazepines](https://psychonautwiki.org/wiki/Benzodiazepines) are combined with other [depressants](https://psychonautwiki.org/wiki/Depressants) such as [opiates](https://psychonautwiki.org/wiki/Opiates) , [barbiturates](https://psychonautwiki.org/wiki/Barbiturates) , [gabapentinoids](https://psychonautwiki.org/wiki/Gabapentinoids) , [thienodiazepines](https://psychonautwiki.org/wiki/Thienodiazepines) , [alcohol](https://psychonautwiki.org/wiki/Alcohol) or other [GABAergic substances](https://psychonautwiki.org/wiki/GABA#GABA_receptors) .**
 
It is strongly discouraged to combine these substances, particularly in [common](https://psychonautwiki.org/wiki/Common) to [heavy](https://psychonautwiki.org/wiki/Heavy) doses.
## Subjective effects

***Disclaimer:** The effects listed below cite the [Subjective Effect Index](https://psychonautwiki.org/wiki/Subjective_effect_index) ( **SEI** ), an open research literature based on anecdotal user reports and the personal analyses of [PsychonautWiki](https://psychonautwiki.org/wiki/PsychonautWiki) [contributors](https://psychonautwiki.org/wiki/Special:TopUsers) . As a result, they should be viewed with a healthy degree of skepticism.*

*It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. *Likewise, **adverse effects** become increasingly likely with higher doses and may include **addiction, severe injury, or death*** ☠.*
### Physical effects
 
- - **[Sedation](https://psychonautwiki.org/wiki/Sedation)** - In terms of energy level alterations, this drug is considerably unique in that it tends to be notably less sedating and less inebriating than other classical or standard [benzodiazepines](https://psychonautwiki.org/wiki/Benzodiazepines) such as [alprazolam](https://psychonautwiki.org/wiki/Alprazolam) , [clonazepam](https://psychonautwiki.org/wiki/Clonazepam) , and [lorazepam](https://psychonautwiki.org/wiki/Lorazepam) . In some sense, it may be seen by many users as more “relaxing” in terms of description rather than being thoroughly “sedating” at average doses. However, at sufficient enough doses sedation does become a salient and unavoidable effect at a certain point. Therefore, presumably at stronger doses this causes users to feel extreme somnolence, forcing them to sit down as they tend to generally feel as if they are constantly on the verge of passing out instead of being physically mobile or consciously alert. This component increases proportional to dosage and eventually becomes powerful enough to force a person into complete unconsciousness.
- **[Muscle relaxation](https://psychonautwiki.org/wiki/Muscle_relaxation)** - In comparison to [alprazolam](https://psychonautwiki.org/wiki/Alprazolam) (Xanax), bromazepam results in a greater degree of muscle relaxation.
- **[Motor control loss](https://psychonautwiki.org/wiki/Motor_control_loss)**
- **[Respiratory depression](https://psychonautwiki.org/wiki/Respiratory_depression)**
- **[Dizziness](https://psychonautwiki.org/wiki/Dizziness)** - This symptom is usually much less prevalent compared to typical, (“heavier”) benzodiazepines like clonazepam or lorazepam.
- **[Seizure suppression](https://psychonautwiki.org/wiki/Seizure_suppression)**
- **[Physical euphoria](https://psychonautwiki.org/wiki/Physical_euphoria)** ### Visual effects
 
- - **[Visual acuity suppression](https://psychonautwiki.org/wiki/Visual_acuity_suppression)** ### Paradoxical effects
 
- Paradoxical reactions to [benzodiazepines](https://psychonautwiki.org/wiki/Benzodiazepines) such as increased seizures (in epileptics), aggression, increased anxiety, violent behavior, loss of impulse control, irritability and suicidal behavior sometimes occur (although they are rare in the general population, with an incidence rate below 1%). 
These paradoxical effects occur with greater frequency in recreational abusers, individuals with mental disorders, children, and patients on high-dosage regimes. ### Cognitive effects
 
- The most prominent of these cognitive effects generally include: 
- **[Anxiety suppression](https://psychonautwiki.org/wiki/Anxiety_suppression)** - Less pronounced than with [alprazolam](https://psychonautwiki.org/wiki/Alprazolam) , especially in regards to panic attacks but may have an upper-hand on many other benzodiazepines in this department due to a very lightly euphoric and subtle, but not uncommon comfortable sense of well-being that is not usually associated with other benzodiazepines.
- **[Disinhibition](https://psychonautwiki.org/wiki/Disinhibition)**
- **[Delusions of sobriety](https://psychonautwiki.org/wiki/Delusions)** - This is the false belief that one is perfectly sober despite obvious evidence to the contrary such as severe cognitive impairment and an inability to fully communicate with others. It most commonly occurs at heavy dosages.
- **[Thought deceleration](https://psychonautwiki.org/wiki/Thought_deceleration)**
- **[Analysis suppression](https://psychonautwiki.org/wiki/Analysis_suppression)**
- **[Amnesia](https://psychonautwiki.org/wiki/Amnesia)**
- **[Memory suppression](https://psychonautwiki.org/wiki/Memory_suppression)**
- **[Increased music appreciation](https://psychonautwiki.org/wiki/Increased_music_appreciation)**
- **[Compulsive redosing](https://psychonautwiki.org/wiki/Compulsive_redosing)**
- **[Emotion suppression](https://psychonautwiki.org/wiki/Emotion_suppression)**
- **[Motivation suppression](https://psychonautwiki.org/wiki/Motivation_suppression)**
- **[Language suppression](https://psychonautwiki.org/wiki/Language_suppression)** - Bromazepam & most benzodiazepines are known to cause slurred speech and difficulty communicating words in a clear fashion. ### After effects
 
- - **[Rebound anxiety](https://psychonautwiki.org/wiki/Anxiety)** - Rebound anxiety is a commonly observed effect with [anxiety relieving](https://psychonautwiki.org/wiki/Anxiety_suppression) substances like [benzodiazepines](https://psychonautwiki.org/wiki/Benzodiazepines) . It typically corresponds to the total duration spent under the substance's influence along with the total amount consumed in a given period, an effect which can easily lend itself to cycles of dependence and addiction.
- **[Dream potentiation](https://psychonautwiki.org/wiki/Dream_potentiation)** or **[Dream suppression](https://psychonautwiki.org/wiki/Dream_suppression)**
- **[Residual sleepiness](https://psychonautwiki.org/wiki/Sleepiness)** - While benzodiazepines can be used as an effective [sleep-inducing](https://psychonautwiki.org/wiki/Hypnotic) aid, their effects may persist into the morning afterward, which may lead users to feeling "groggy" or "dull" for up to a few hours.
- **[Thought deceleration](https://psychonautwiki.org/wiki/Thought_deceleration)**
- **[Thought disorganization](https://psychonautwiki.org/wiki/Thought_disorganization)**
- **[Irritability](https://psychonautwiki.org/wiki/Irritability)**
## Toxicity and harm potential

Bromazepam has a low toxicity relative to dose. However, it is potentially [lethal](https://psychonautwiki.org/wiki/Respiratory_depression) when mixed with [depressants](https://psychonautwiki.org/wiki/Depressants) like [alcohol](https://psychonautwiki.org/wiki/Alcohol) or [opioids](https://psychonautwiki.org/wiki/Opioids) . It is strongly recommended that one use [harm reduction practices](https://psychonautwiki.org/wiki/Responsible_drug_use) .

### Contexutal Risks

High dosage of bromazepam causes [disinhibition](https://psychonautwiki.org/wiki/Disinhibition) , [memory suppression](https://psychonautwiki.org/wiki/Memory_suppression) , [analysis depression](https://psychonautwiki.org/wiki/Analysis_depression) and [motor control loss](https://psychonautwiki.org/wiki/Motor_control_loss) . Moreover, paradoxal effects can occure and include agressivity and impulsive behaviour. These effects can provoke contextual harms such as social reprobation due to improper behaviour, falling, being wounded, or harming someone else.

### Risks of long-term use

The problems associated with the long-term use of [benzodiazepines](https://psychonautwiki.org/wiki/Benzodiazepines) (the chemical class of bromazepam) may include : impaired cognitive abilities, memory problems, mood swings, overdoses when combined with other drugs, disinhibition, depression, perceptual disturbances, depersonalization, and sexual dysfunction. However, the most important consequence of long-term use of benzodiazepines is the development of dependence.

### Lethal dosage

The acute toxic dose, which means that it damages physically the body in one intake, has been estimated to 180mg (oral) for an adult, without combinaison or tolerance.

### Tolerance and addiction potential

Tolerance to the behavioral effects of benzodiazepines appears within different period of times regarding the effects considered ; but in general, it appears within several days of continuous use.

The shortest period for developing dependence due to the continuous use of [benzodiazepines](https://psychonautwiki.org/wiki/Benzodiazepines) varies in the different studies : from one month to six. Benzodiazepine dependence is more prevalent among women who are middle aged, separated, of low educational background, unemployed or housewives.

### Dangerous interactions

Although many drugs are safe on their own, they can become dangerous and even life-threatening when combined with other substances. The list below contains some common potentially dangerous combinations, but may not include all of them. Certain combinations may be safe in low doses of each but still increase the potential risk of death. [Independent research](https://www.google.com/) should always be done to ensure that a combination of two or more substances is safe before consumption.

- **Depressants** ( *[1,4-Butanediol](https://psychonautwiki.org/wiki/1,4-Butanediol) , [2-methyl-2-butanol](https://psychonautwiki.org/wiki/2-methyl-2-butanol) , [alcohol](https://psychonautwiki.org/wiki/Alcohol) , [barbiturates](https://psychonautwiki.org/wiki/Barbiturates) , [GHB](https://psychonautwiki.org/wiki/GHB) / [GBL](https://psychonautwiki.org/wiki/GBL) , [methaqualone](https://psychonautwiki.org/wiki/Methaqualone) , [opioids](https://psychonautwiki.org/wiki/Opioids)* ) - This combination can result in dangerous or even fatal levels of [respiratory depression](https://psychonautwiki.org/wiki/Respiratory_depression) . These substances potentiate the [muscle relaxation](https://psychonautwiki.org/wiki/Muscle_relaxation) , [sedation](https://psychonautwiki.org/wiki/Sedation) and [amnesia](https://psychonautwiki.org/wiki/Amnesia) caused by one another and can lead to unexpected loss of consciousness at high doses. There is also an increased risk of vomiting during unconsciousness and death from the resulting suffocation. If this occurs, users should attempt to fall asleep in the [recovery position](https://psychonautwiki.org/wiki/Recovery_position) or have a friend move them into it.
- **Dissociatives** - This combination can result in an increased risk of vomiting during unconsciousness and death from the resulting suffocation. If this occurs, users should attempt to fall asleep in the [recovery position](https://psychonautwiki.org/wiki/Recovery_position) or have a friend move them into it.
- **Stimulants** - It is dangerous to combine benzodiazepines with [stimulants](https://psychonautwiki.org/wiki/Stimulant) due to the risk of excessive intoxication. Stimulants decrease the [sedative](https://psychonautwiki.org/wiki/Sedation) effect of benzodiazepines, which is the main factor most people consider when determining their level of intoxication. Once the stimulant wears off, the effects of benzodiazepines will be significantly increased, leading to intensified [disinhibition](https://psychonautwiki.org/wiki/Disinhibition) as well as [other effects](https://psychonautwiki.org/wiki/Benzodiazepine#Subjective_effects) . If combined, one should strictly limit themselves to only dosing a certain amount of benzodiazepines per hour. This combination can also potentially result in severe dehydration if hydration is not monitored.

## Legal status

Internationally, Bromazepam is a Schedule IV controlled drug under the Convention on Psychotropic Substances. Bromazepam is regulated in most countries as a prescription drug.

## See also

- [Responsible use](https://psychonautwiki.org/wiki/Responsible_use)
- [Benzodiazepines](https://psychonautwiki.org/wiki/Benzodiazepines)
- [Diazepam](https://psychonautwiki.org/wiki/Diazepam)

## External links

- [Bromazepam (Wikipedia)](https://en.wikipedia.org/wiki/Bromazepam)
- [Bromazepam (Erowid Vault)](https://www.erowid.org/pharms/bromazepam/bromazepam.shtml)
- [Bromazepam (DrugBank)](https://go.drugbank.com/drugs/DB01558)

## References
1. ↑ [Risks of Combining Depressants - TripSit](https://tripsit.me/combining-depressants/)
2. ↑ [https://go.drugbank.com/drugs/DB01558](https://go.drugbank.com/drugs/DB01558)
3. ↑ Saïas, T., Gallarda, T. (September 2008). "[Paradoxical aggressive reactions to benzodiazepine use: a review]".*L’Encephale*.**34**(4): 330–336.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1016/j.encep.2007.05.005](//doi.org/10.1016%2Fj.encep.2007.05.005).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0013-7006](//www.worldcat.org/issn/0013-7006).
4. ↑ Paton, C. (December 2002).["Benzodiazepines and disinhibition: a review"](https://www.cambridge.org/core/journals/psychiatric-bulletin/article/benzodiazepines-and-disinhibition-a-review/421AF197362B55EDF004700452BF3BC6).*Psychiatric Bulletin*.**26**(12): 460–462.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1192/pb.26.12.460](//doi.org/10.1192%2Fpb.26.12.460).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0955-6036](//www.worldcat.org/issn/0955-6036).
5. ↑ Bond, A. J. (1 January 1998).["Drug- Induced Behavioural Disinhibition"](https://doi.org/10.2165/00023210-199809010-00005).*CNS Drugs*.**9**(1): 41–57.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.2165/00023210-199809010-00005](//doi.org/10.2165%2F00023210-199809010-00005).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[1179-1934](//www.worldcat.org/issn/1179-1934).
6. ↑ Drummer, O. H. (February 2002). "Benzodiazepines - Effects on Human Performance and Behavior".*Forensic Science Review*.**14**(1–2): 1–14.[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[1042-7201](//www.worldcat.org/issn/1042-7201).
7. ↑ Goyal, S. (14 March 1970). "Drugs and dreams".*Canadian Medical Association Journal*.**102**(5): 524.[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0008-4409](//www.worldcat.org/issn/0008-4409).
8. ↑ [https://accpjournals.onlinelibrary.wiley.com/doi/abs/10.1592/phco.24.13.1177.38089](https://accpjournals.onlinelibrary.wiley.com/doi/abs/10.1592/phco.24.13.1177.38089)
9. ↑ [https://erowid.org/experiences/exp.php?ID=68026](https://erowid.org/experiences/exp.php?ID=68026)
10. ↑ [https://www.tandfonline.com/doi/full/10.1080/14659891.2019.1581283](https://www.tandfonline.com/doi/full/10.1080/14659891.2019.1581283)
11. ↑ [https://pubmed.ncbi.nlm.nih.gov/16856084/](https://pubmed.ncbi.nlm.nih.gov/16856084/)
12. ↑ [https://jnnp.bmj.com/content/76/12/1746.3](https://jnnp.bmj.com/content/76/12/1746.3)
13. ↑ [https://academic.oup.com/book/24485/chapter-abstract/187578126?login=false](https://academic.oup.com/book/24485/chapter-abstract/187578126?login=false)
14. ↑ [https://pubmed.ncbi.nlm.nih.gov/1987812/](https://pubmed.ncbi.nlm.nih.gov/1987812/)
15. ↑ [https://www.sfmu.org/toxin/DOSETOXI/DOSETOX.HTM](https://www.sfmu.org/toxin/DOSETOXI/DOSETOX.HTM)
16. ↑ [https://pubmed.ncbi.nlm.nih.gov/2858076/](https://pubmed.ncbi.nlm.nih.gov/2858076/)
17. ↑ [https://onlinelibrary.wiley.com/doi/10.1111/j.1360-0443.1981.tb00218.x](https://onlinelibrary.wiley.com/doi/10.1111/j.1360-0443.1981.tb00218.x)
18. ↑ [https://link.springer.com/article/10.1007/s00213-002-1376-8](https://link.springer.com/article/10.1007/s00213-002-1376-8)
19. ↑ [https://pubmed.ncbi.nlm.nih.gov/2897976/](https://pubmed.ncbi.nlm.nih.gov/2897976/)
20. ↑ [https://link.springer.com/article/10.1007/s00213-002-1376-8](https://link.springer.com/article/10.1007/s00213-002-1376-8)
21. ↑ International Narcotics Control Board (2003) | [http://infoespai.org/wp-content/uploads/2014/12/green.pdf](http://infoespai.org/wp-content/uploads/2014/12/green.pdf)NewPP limit report Cached time: 20251218075224 Cache expiry: 1209600 Dynamic content: false Complications: [] [SMW] In‐text annotation parser time: 0.043 seconds CPU time usage: 0.290 seconds Real time usage: 0.493 seconds Preprocessor visited node count: 1356/1000000 Post‐expand include size: 101342/2097152 bytes Template argument size: 18400/2097152 bytes Highest expansion depth: 12/40 Expensive parser function count: 0/100 Unstrip recursion depth: 0/20 Unstrip post‐expand size: 13307/5000000 bytes Lua time usage: 0.130/7 seconds Lua virtual size: 7.03 MB/50 MB Lua estimated memory usage: 0 bytes ExtLoops count: 11Transclusion expansion time report (%,ms,calls,template) 100.00% 374.779 1 -total 24.78% 92.875 5 Template:Cite_journal 21.89% 82.029 2 Template:Headerpanel 19.65% 73.631 1 Template:DepressantOD 19.25% 72.147 1 Template:SubstanceBox/Bromazepam 18.67% 69.982 1 Template:GenericPanel/warning 18.43% 69.054 1 Template:Citation 17.98% 67.387 1 Template:SubstanceBox 17.72% 66.394 1 Template:GenericPanel 9.92% 37.188 1 Template:Effects/base`,
  "tripsit-factsheets": `# Bromazepam
*Source: https://tripbot.tripsit.me/api/tripsit/getDrug/bromazepam*

## Classification
- **Categories:** benzodiazepine, habit-forming, depressant
- **Also known as:** lectopam, lexilium, lexotan, brazepam, lexotanil

## Dosage

### Oral
- **Common:** 5-10mg
- **Heavy:** 10-15mg+
- **Light:** 2.5-5mg

## Duration
- **Onset:** 10-20 minutes
- **Duration:** 4-8 hours
- **After Effects:** 1-16 hours

## Effects
- Anxiolytic
- Sedative
- Muscle Relaxant
- Amnesia
- Dystaxia
`,
  "wikipedia": `# Bromazepam
*Source: https://en.wikipedia.org/wiki/Bromazepam*

Bromazepam, sold under many brand names, is a benzodiazepine. It is mainly an anti-anxiety agent with similar side effects to diazepam. In addition to being used to treat anxiety or panic states, bromazepam may be used as a premedicant prior to minor surgery. Bromazepam typically comes in doses of 1.5 mg, 3 mg and 6 mg tablets.
It was patented in 1961 by Roche and approved for medical use in 1974.

## Medical uses

Medical uses include treatment of severe anxiety. Despite certain side effects and the emergence of alternative products (e.g. pregabalin), benzodiazepine medication remains an effective way of reducing problematic symptoms, and is typically deemed effective by patients and medical professionals.
Similarly to other intermediate-acting depressants, it may be used as hypnotic medication, though prescribing for insomnia is generally limited to a maximum of four weeks due to dependence risks and limited long-term efficacy or in order to mitigate withdrawal effects of alcohol consumption.

## Pharmacology

Bromazepam is a "classical" benzodiazepine; other classical benzodiazepines include: diazepam, clonazepam, oxazepam, lorazepam, nitrazepam, flurazepam, and clorazepate. Its molecular structure is composed of a diazepine connected to a benzene ring and a pyridine ring, the benzene ring having a single nitrogen atom that replaces one of the carbon atoms in the ring structure. It is a 1,4-benzodiazepine, which means that the nitrogens on the seven-sided diazepine ring are in the 1 and 4 positions.
Bromazepam binds to the GABA receptor GABAA, causing a conformational change and increasing the inhibitory effects of GABA. It acts as a positive modulator, increasing the receptors' response when activated by GABA itself or an agonist (such as alcohol). As opposed to barbital, BZDs are not GABA-receptor activators and rely on increasing the neurotransmitter's natural activity. Bromazepam is an intermediate-acting benzodiazepine, is moderately lipophilic compared to other substances of its class and metabolised hepatically via oxidative pathways. It does not possess any antidepressant or antipsychotic qualities.
After night time administration of bromazepam a highly significant reduction of gastric acid secretion occurs during sleep followed by a highly significant rebound in gastric acid production the following day.
Bromazepam alters the electrical status of the brain causing an increase in beta activity and a decrease in alpha activity in EEG recordings.

### Pharmacokinetics

Bromazepam is reported to be metabolized by a hepatic enzyme belonging to the Cytochrome P450 family of enzymes. In 2003, a team led by Oda Manami at Oita Medical University reported that CYP3A4, a member of the Cytochrome P450 family, was not the responsible enzyme since itraconazole, a known inhibitor of CYP3A4, did not affect its metabolism. In 1995, J. van Harten at the Solvay Pharmaceutical Department of Clinical Pharmacology in Weesp reported that fluvoxamine, which is a potent inhibitor of CYP1A2, a less potent CYP3A4 inhibitor, and a negligible inhibitor of CYP2D6, does inhibit its metabolism.
The major metabolite of bromazepam is hydroxybromazepam, which is an active agent too and has a half-life approximately equal to that of bromazepam.

## Side-effects

Bromazepam is similar in side effects to other benzodiazepines. The most common side effects reported are drowsiness, sedation, ataxia, memory impairment, and dizziness. Impairments to memory functions are common with bromazepam and include a reduced working memory and reduced ability to process environmental information. A 1975 experiment on healthy, male college students exploring the effects of four different drugs on learning capacity observed that taking bromazepam alone at 6 mg 3 times daily for 2 weeks impaired learning capacities significantly. In combination with alcohol, impairments in learning capacity became even more pronounced. Various studies report impaired memory, visual information processing and sensory data and impaired psychomotor performance; deterioration of cognition including attention capacity and impaired co-ordinative skills; impaired reactive and attention performance, which can impair driving skills; drowsiness and decrease in libido. Unsteadiness after taking bromazepam is, however, less pronounced than other benzodiazepines such as lorazepam.
On occasion, benzodiazepines can induce extreme alterations in memory such as anterograde amnesia and amnesic automatism, which may have medico-legal consequences. Such reactions occur usually only at the higher dose end of the prescribing spectrum.
Very rarely, dystonia can develop.
Up to 30% treated on a long-term basis develop a form of dependence, i.e. these patients cannot stop the medication without experiencing physical and/or psychological benzodiazepine withdrawal symptoms.
Leukopenia and liver-damage of the cholestatic type with or without jaundice (icterus) have additionally been seen; the original manufacturer Roche recommends regular laboratory examinations to be performed routinely.
Ambulatory patients should be warned that bromazepam may impair the ability to drive vehicles and to operate machinery. The impairment is worsened by consumption of alcohol, because both act as central nervous system depressants. During the course of therapy, tolerance to the sedative effect usually develops.

### Frequency and seriousness of adverse effects

As with all medication, the frequency and seriousness of side-effects varies greatly depending on quantities consumed. In a study about bromazepam's negative effects on psychomotor skills and driving ability, it was noted that 3 mg doses caused minimal impairment. It also appeared that impairment may be tied to methods of testing more so than on the product's intrinsic activity.
Moreover, side-effects other than drowsiness, dizziness and ataxia seem to be rare and not experienced by more than a few percent of users. The use of other, comparable medication seems to display an identically moderate side-effect profile.

### Tolerance, dependence and withdrawal

Prolonged use of bromazepam can cause tolerance and may lead to both physical and psychological dependence on the drug, and as a result, it is a medication which is controlled by international law. It is nonetheless important to note that dependence, long-term use and misuse occur in a minority of cases and are not representative of most patients' experience with this type of medication.
It shares with other benzodiazepines the risk of abuse, misuse, psychological dependence or physical dependence. A withdrawal study demonstrated both psychological dependence and physical dependence on bromazepam including marked rebound anxiety after 4 weeks chronic use. Those whose dose was gradually reduced experienced no withdrawal.
Patients treated with bromazepam for generalised anxiety disorder were found to experience withdrawal symptoms such as a worsening of anxiety, as well as the development of physical withdrawal symptoms when abruptly withdrawn bromazepam. Abrupt or over rapid withdrawal from bromazepam after chronic use even at therapeutic prescribed doses can lead to a severe withdrawal syndrome including status epilepticus and a condition resembling delerium tremens.
Animal studies have shown that chronic administration of diazepam (or bromazepam) causes a decrease in spontaneous locomotor activity, decreased turnover of noradrenaline and dopamine and serotonin, increased activity of tyrosine hydroxylase and increased levels of the catecholamines. During withdrawal of bromazepam or diazepam a fall in tryptophan, serotonin levels occurs as part of the benzodiazepine withdrawal syndrome. Changes in the levels of these chemicals in the brain can cause headaches, anxiety, tension, depression, insomnia, restlessness, confusion, irritability, sweating, dysphoria, dizziness, derealization, depersonalization, numbness/tingling of extremities, hypersensitivity to light, sound, and smell, perceptual distortions, nausea, vomiting, diarrhea, appetite loss, hallucinations, delirium, seizures, tremor, stomach cramps, myalgia, agitation, palpitations, tachycardia, panic attacks, short-term memory loss, and hyperthermia.

### Overdose

Bromazepam is commonly involved in drug overdoses. A severe bromazepam benzodiazepine overdose may result in an alpha pattern coma type. The toxicity of bromazepam in overdosage increases when combined with other CNS depressant drugs such as alcohol or sedative hypnotic drugs. Similarly to other benzodiazepines however, being a positive modulator of certain neuroreceptors and not an agonist, the product has reduced overdose potential compared to older products of the barbiturate class. Its consumption alone is very seldom fatal in healthy adults.
Bromazepam was in 2005 the most common benzodiazepine involved in intentional overdoses in France. Bromazepam has also been responsible for accidental poisonings in companion animals. A review of benzodiazepine poisonings in cats and dogs from 1991 to 1994 found bromazepam to be responsible for significantly more poisonings than any other benzodiazepine.

## Contraindications

Benzodiazepines require special precaution if used in elderly, pregnant, child, alcohol- or drug-dependent individuals and individuals with comorbid psychiatric disorders.

### Special populations

Globally, bromazepam is contraindicated and should be used with caution in women who are pregnant, the elderly, patients with a history of alcohol or other substance abuse disorders and children.
In 1987, a team of scientists led by Ochs reported that the elimination half-life, peak serum concentration, and serum free fraction are significantly elevated and the oral clearance and volume of distribution significantly lowered in elderly subjects. The clinical consequence is that the elderly should be treated with lower doses than younger patients.
Bromazepam may affect driving and ability to operate machinery.
Bromazepam is pregnancy category D, a classification that means that bromazepam has been shown to cause harm to the unborn child. The Hoffman LaRoche product information leaflet warns against breast feeding while taking bromazepam. There has been at least one report of sudden infant death syndrome linked to breast feeding while consuming bromazepam.

## Interactions

Cimetidine, fluvoxamine and propranolol causes a marked increase in the elimination half-life of bromazepam leading to increased accumulation of bromazepam.

## Society and culture

### Drug misuse

Bromazepam has a similar misuse risk as other benzodiazepines such as diazepam. In France car accidents involving psychotropic drugs in combination with alcohol (itself a major contributor) found benzodiazepines, mainly diazepam, nordiazepam, and bromazepam, to be the most common drug present in the blood stream, almost twice that of the next-most-common drug cannabis. Bromazepam has also been used in serious criminal offences including robbery, homicide, and sexual assault.

### Brand names

It is marketed under several brand names, including, Brozam, Lectopam, Lexomil, Lexotan, Lexilium, Lexaurin, Brazepam, Rekotnil, Bromaze, Somalium, Lexatin, Calmepam, Zepam and Lexotanil.

### Legal status

Bromazepam is a Schedule IV drug under the Convention on Psychotropic Substances.

### Synthesis
`,
};
